Clinical trials: Treatment Resistant Depression
Treatment Resistant Major Depressive Disorder
DBS of the Lateral Habenula in Treatment-Resistant Depression
This research study will investigate the safety, tolerability, and benefit of bilateral deep brain stimulation (DBS) to the lateral habenula in subjects with treatment-resistant major depression (TRD) secondary to either…
- Trial name
- NCT01798407
- Testing
- Activa Tremor Control Sys (DBS Implant), Randomized, staggered withdrawal phase
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Wayne Goodman MD
Depression
Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)
The primary aims of this study are to: 1. Assess the efficacy of aripiprazole augmentation for the acute and continuation treatment of TRLLD.
- Trial name
- IRL GREY (NCT00892047)
- Testing
- venlafaxine XR plus aripiprazole
- Where
- 3 sites in United States, Canada
- Volunteers
- 468 people
- Sponsor
- University of Pittsburgh
Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD)
Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study
The investigators propose a single-arm, open-label study to evaluate the effectiveness, safety, tolerability and feasibility of at-home transcranial direct current stimulation (tDCS) as a treatment for depression, particularly in…
- Trial name
- NCT07217223
- Testing
- Spaced Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Diego
Depression
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression
This study aims to examine the antidepressant efficacy of riluzole, employing a randomized, double-blind, placebo-controlled, adjunctive trial in treatment-resistant major depressive disorder (TRD).
- Trial name
- NCT01204918
- Testing
- Riluzole
- Where
- 3 sites in United States
- Volunteers
- 104 people
- Sponsor
- Yale University
Treatment Resistant Depression (TRD)
Ketamine Biomarker Validation
An EEG-based biomarker will be developed for the effects of ketamine infusion in patients with Depression. The effects of ketamine infusion on Depression symptoms and EEG signals will be analyzed.
- Trial name
- NCT07307768
- Testing
- Ketamine (0.25 mg/kg), Ketamine (0.5 mg/kg), Ketamine (0.75 mg/kg)
- Where
- United States
- Sponsor
- Soterix Medical
Treatment Resistant Depression, Visual Perceptual Weakness
Positron Emission Tomography in Transcranial Magnetic Stimulation Intervention for Treatment-resistant Depression
Major depressive disorder (MDD) exhibit reduced visual motor perception, which affects prognosis. Metabolic substance changes and abnormal neural activity in the middle temporal visual area (MT) mediate this perceptual…
- Trial name
- NCT06044324
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Schizophrenia, Treatment Resistant Depression
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.
- Conditions
- Schizophrenia, Treatment Resistant Depression, Aging, Premature
- Trial name
- NCT05838560
- Testing
- Dasatinib, quercetin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Depressive Disorder, Bipolar Disorder
Multimodal Biomarkers of Electroconvulsive Therapy in Severe and Treatment-resistant Depression
Electroconvulsive therapy (ECT) is a widespread and safe stimulation method that has been used successfully for decades in psychiatric diseases such as severe or therapy-resistant depression.
- Trial name
- DetECT (NCT05463562)
- Where
- Germany
- Volunteers
- 134 people
- Sponsor
- Max-Planck-Institute of Psychiatry